111 Capital Lowers Stock Holdings in Hologic, Inc. $HOLX

111 Capital cut its holdings in Hologic, Inc. (NASDAQ:HOLX) by 43.6% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 9,077 shares of the medical equipment provider’s stock after selling 7,008 shares during the period. 111 Capital’s holdings in Hologic were worth $613,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Hologic by 10.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,776 shares of the medical equipment provider’s stock worth $2,395,000 after buying an additional 3,520 shares during the period. Empowered Funds LLC increased its stake in shares of Hologic by 27.7% during the 1st quarter. Empowered Funds LLC now owns 17,494 shares of the medical equipment provider’s stock valued at $1,081,000 after acquiring an additional 3,790 shares during the last quarter. Assetmark Inc. lifted its holdings in shares of Hologic by 22.0% during the 2nd quarter. Assetmark Inc. now owns 3,285 shares of the medical equipment provider’s stock worth $214,000 after acquiring an additional 593 shares during the period. South Dakota Investment Council boosted its position in shares of Hologic by 68.0% in the second quarter. South Dakota Investment Council now owns 12,600 shares of the medical equipment provider’s stock worth $821,000 after acquiring an additional 5,100 shares during the last quarter. Finally, K.J. Harrison & Partners Inc purchased a new stake in Hologic in the second quarter valued at approximately $1,987,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Wall Street Analysts Forecast Growth

HOLX has been the topic of a number of research analyst reports. Morgan Stanley lifted their price target on shares of Hologic from $69.00 to $76.00 and gave the company an “equal weight” rating in a report on Tuesday, November 11th. Weiss Ratings restated a “hold (c)” rating on shares of Hologic in a research note on Wednesday, January 28th. Needham & Company LLC reaffirmed a “hold” rating on shares of Hologic in a research note on Tuesday, November 4th. Evercore cut Hologic from an “outperform” rating to an “in-line” rating and decreased their target price for the stock from $79.00 to $78.00 in a report on Monday, January 5th. Finally, Argus lowered shares of Hologic from a “buy” rating to a “hold” rating in a report on Monday, January 12th. Two investment analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $78.42.

Hologic Trading Up 0.1%

NASDAQ HOLX opened at $75.45 on Tuesday. The stock has a market cap of $16.84 billion, a P/E ratio of 31.44, a PEG ratio of 2.24 and a beta of 0.73. The company’s fifty day simple moving average is $74.96 and its 200-day simple moving average is $72.22. The company has a current ratio of 4.04, a quick ratio of 3.32 and a debt-to-equity ratio of 0.48. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $75.49.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). Hologic had a net margin of 13.18% and a return on equity of 19.58%. The firm had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same period in the previous year, the business posted $0.87 earnings per share. Hologic’s revenue for the quarter was up 2.5% on a year-over-year basis. Equities research analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.